The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy

Drug-induced thrombotic microangiopathy (DITMA) is a secondary cause of thrombotic microangiopathy and a potentially fatal inflammatory disease. DITMA has been attributed to a variety of drugs, particularly chemotherapeutic and immunosuppressive agents. Prompt diagnosis is critical for survival and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabr, Jihad Ben, Bilal, Hiba, Mirchia, Kanish, Perl, Andras
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412890/
https://www.ncbi.nlm.nih.gov/pubmed/32757799
http://dx.doi.org/10.1177/2324709620947266
_version_ 1783568699771322368
author Gabr, Jihad Ben
Bilal, Hiba
Mirchia, Kanish
Perl, Andras
author_facet Gabr, Jihad Ben
Bilal, Hiba
Mirchia, Kanish
Perl, Andras
author_sort Gabr, Jihad Ben
collection PubMed
description Drug-induced thrombotic microangiopathy (DITMA) is a secondary cause of thrombotic microangiopathy and a potentially fatal inflammatory disease. DITMA has been attributed to a variety of drugs, particularly chemotherapeutic and immunosuppressive agents. Prompt diagnosis is critical for survival and treatment necessitates withdrawal of the offending drug; however, many cases require further treatment including plasmapheresis, immunosuppression, and anticoagulation. In this article, we report a cutaneous biopsy-proven case of tacrolimus-induced DITMA, which was successfully treated with eculizumab after failing the conventional standard of care.
format Online
Article
Text
id pubmed-7412890
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74128902020-08-19 The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy Gabr, Jihad Ben Bilal, Hiba Mirchia, Kanish Perl, Andras J Investig Med High Impact Case Rep Case Report Drug-induced thrombotic microangiopathy (DITMA) is a secondary cause of thrombotic microangiopathy and a potentially fatal inflammatory disease. DITMA has been attributed to a variety of drugs, particularly chemotherapeutic and immunosuppressive agents. Prompt diagnosis is critical for survival and treatment necessitates withdrawal of the offending drug; however, many cases require further treatment including plasmapheresis, immunosuppression, and anticoagulation. In this article, we report a cutaneous biopsy-proven case of tacrolimus-induced DITMA, which was successfully treated with eculizumab after failing the conventional standard of care. SAGE Publications 2020-08-06 /pmc/articles/PMC7412890/ /pubmed/32757799 http://dx.doi.org/10.1177/2324709620947266 Text en © 2020 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Gabr, Jihad Ben
Bilal, Hiba
Mirchia, Kanish
Perl, Andras
The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
title The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
title_full The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
title_fullStr The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
title_full_unstemmed The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
title_short The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
title_sort use of eculizumab in tacrolimus-induced thrombotic microangiopathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412890/
https://www.ncbi.nlm.nih.gov/pubmed/32757799
http://dx.doi.org/10.1177/2324709620947266
work_keys_str_mv AT gabrjihadben theuseofeculizumabintacrolimusinducedthromboticmicroangiopathy
AT bilalhiba theuseofeculizumabintacrolimusinducedthromboticmicroangiopathy
AT mirchiakanish theuseofeculizumabintacrolimusinducedthromboticmicroangiopathy
AT perlandras theuseofeculizumabintacrolimusinducedthromboticmicroangiopathy
AT gabrjihadben useofeculizumabintacrolimusinducedthromboticmicroangiopathy
AT bilalhiba useofeculizumabintacrolimusinducedthromboticmicroangiopathy
AT mirchiakanish useofeculizumabintacrolimusinducedthromboticmicroangiopathy
AT perlandras useofeculizumabintacrolimusinducedthromboticmicroangiopathy

Ejemplares similares